2. Cell Cycle/DNA Damage Cytoskeleton Antibody-drug Conjugate/ADC Related
  3. Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)
  4. Anetumab ravtansine

Anetumab ravtansine  (Synonyms: BAY 94-9343)

Cat. No.: HY-141606
Technical Support

Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models.

For research use only. We do not sell to patients.

Anetumab ravtansine Chemical Structure

Anetumab ravtansine Chemical Structure

CAS No. : 1375258-01-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anetumab ravtansine Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models[1].

In Vitro

Anetumab ravtansine (0.01-300 nM; 4 or 24 h) demonstrates potent and selective cytotoxicity of mesothelin-expressing cells with an IC50 of 0.72 nM, without affecting mesothelin-negative or nonproliferating cells[1].
Anetumab ravtansine induces a bystander effect on neighboring mesothelin-negative tumor cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anetumab ravtansine Related Antibodies

Cell Viability Assay[1]

Cell Line: MIA PaCa-2 and HT-29; OVCAR-3; and NCI-H226
Concentration: 0.01 nM-300 nM
Incubation Time: 24 hours
Result: Inhibited cell viability with IC50s of 1.59 nM (MIA PaCa-2), 0.715 nM (HT-29), 1.59 nM (OVCAR-3), and 5.72 nM (NCI-H226), respectively.
In Vivo

Anetumab ravtansine (10 mg/kg; i.v.) is localized specifically to mesothelin-positive tumors and inhibits tumor growth in both subcutaneous and orthotopic xenograft models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Subcutaneous and orthotopic xenograft models: MIA PaCa, HT29, OVCAR-3, NCI-H226 and so on (NMRI nu/nu mice: 18-25 g, 7-10 weeks old)[1]
Dosage: 2.7 mg/kg (0.05 mg/kg DM4), 10.6 mg/kg (0.2 mg/kg DM4)
Administration: MF-T, or S-methyl-DM4 on days 5, 8, and 12 (mice implanted with MIA PaCa or HT29 meso cells); on days 33, 36, and 40 (OVCAR-3); on days 78, 81, 84, 127, 130, and 133 (NCI-H226); on days 15, 18, and 22 (OVCAR-3- s-05 orthotopic); on days 7, 10, and 13 (HT29 titration); Q3Dx3 starting on day 0 (PAXF736); Q3Dx3 starting on day 29 (OVCAR6719); or Q4Dx3 starting on day 34 (Meso7212) after tumor cell inoculation.
Result: Resulted in complete tumor eradication at 10.6 mg/kg (0.2 mg/kg DM4), lasting for at least 17 weeks following the final treatment.
Eradicated tumors in 5 out of 6 animals in the MIA PaCa-2/meso model rather than in HT-29/ meso model at 2.7 mg/kg (0.05 mg/kg DM4).
CAS No.
SMILES

[Anetumab ravtansine]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anetumab ravtansine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anetumab ravtansine1375258-01-7BAY 94-9343Microtubule/TubulinAntibody-Drug Conjugates (ADCs)Antibody-Drug ConjugatesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anetumab ravtansine
Cat. No.:
HY-141606
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.